Literature DB >> 24145312

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

M Massa1, V Rosti2, R Campanelli2, G Fois2, G Barosi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24145312     DOI： 10.1038/leu.2013.296

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Ruxolitinib for myelofibrosis therapy: current context, pros and cons.

Authors:  A Pardanani
Journal:  Leukemia       Date:  2012-07       Impact factor: 11.528

2.  Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?

Authors:  Giovanni Barosi; Umberto Magrini; Robert Peter Gale
Journal:  Leuk Res       Date:  2010-06-09       Impact factor: 3.156

3.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Authors:  A Pardanani; J Hood; T Lasho; R L Levine; M B Martin; G Noronha; C Finke; C C Mak; R Mesa; H Zhu; R Soll; D G Gilliland; A Tefferi
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

4.  Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Authors:  Rowan Wathes; Simon Moule; Dragana Milojkovic
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

5.  Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Authors:  Roger A Goldberg; Elias Reichel; Lauren J Oshry
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

6.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

7.  SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

Authors:  S Hart; K C Goh; V Novotny-Diermayr; C Y Hu; H Hentze; Y C Tan; B Madan; C Amalini; Y K Loh; L C Ong; A D William; A Lee; A Poulsen; R Jayaraman; K H Ong; K Ethirajulu; B W Dymock; J W Wood
Journal:  Leukemia       Date:  2011-06-21       Impact factor: 11.528

8.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Solveig Nora Daecke; Stephanie Wallner; Sowmya Parampalli Yajnanarayana; Christian Kurts; Dominik Wolf; Peter Brossart
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

9.  An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Authors:  Nicholas G Wysham; Donald R Sullivan; Gopal Allada
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

Authors:  Claudia Colomba; Raffaella Rubino; Lucia Siracusa; Francesco Lalicata; Marcello Trizzino; Lucina Titone; Manlio Tolomeo
Journal:  BMC Res Notes       Date:  2012-10-05
View more
  34 in total

Review 1.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  JAK inhibitors and myelofibrosis, Einstein and ruxolitinib.

Authors:  Claire Harrison
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

Review 4.  Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?

Authors:  F Lussana; M Di Ianni; A Rambaldi
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

5.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

6.  Disseminated tuberculosis associated with ruxolitinib.

Authors:  R K Hopman; S J Lawrence; S T Oh
Journal:  Leukemia       Date:  2014-03-13       Impact factor: 11.528

7.  Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

Authors:  Norio Komatsu; Keita Kirito; Kazuya Shimoda; Takayuki Ishikawa; Kohshi Ohishi; Kazuma Ohyashiki; Naoto Takahashi; Hikaru Okada; Taro Amagasaki; Toshio Yonezu; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-11-10       Impact factor: 2.490

Review 8.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 9.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

10.  Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.

Authors:  Samantha C Lee; John Feenstra; Paul R Georghiou
Journal:  BMJ Case Rep       Date:  2014-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.